论文部分内容阅读
目的探讨多西他赛联合替吉奥胶囊对晚期胃癌患者体能状态的影响。方法选取2013年6月至2015年6月88例晚期胃癌患者为研究对象,随机分为观察组与对照组,每组44例。对照组采用多西他赛联合氟尿嘧啶注射液化疗,观察组采用多西他赛联合替吉奥胶囊。比较两组患者化疗后的体能状态及化疗中不良反应的发生情况。结果化疗后观察组体能改善情况明显优于对照组,而下降情况则低于对照组,两组比较差异有统计学意义(P<0.05);对照组不良反应发生率明显高于观察组,差异有统计学意义(P<0.05)。结论晚期胃癌采用多西他赛联合替吉奥胶囊治疗,不良反应相对较少,且能有效稳定患者病情,改善患者的体能状态,具有较高的临床应用价值。
Objective To investigate the effect of Docetaxel and Teglitazon Capsules on the physical status of patients with advanced gastric cancer. Methods A total of 88 patients with advanced gastric cancer from June 2013 to June 2015 were selected as study subjects and randomly divided into observation group and control group with 44 cases in each group. The control group received docetaxel combined with 5-fluorouracil injection chemotherapy, and the observation group received docetaxel combined with getigac capsule. The postoperative state of chemotherapy and the incidence of adverse reactions during chemotherapy were compared between the two groups. Results After treatment, the improvement of body function in the observation group was significantly better than that in the control group, while the decline was lower than that in the control group (P <0.05). The incidence of adverse reactions in the control group was significantly higher than that in the observation group There was statistical significance (P <0.05). Conclusion The treatment of advanced gastric cancer with docetaxel combined with tigei capsule has relatively fewer adverse reactions, and can effectively stabilize the patient’s condition and improve the physical fitness of patients with high clinical value.